Publications by authors named "P Muxi"
Article Synopsis
- The combination of all-trans retinoic acid and anthracyclines has greatly improved acute promyelocytic leukemia (APL) treatment outcomes, particularly in areas without access to arsenic trioxide.
- Despite these advances, low- and middle-income countries (LMIC) still struggle with high mortality rates during treatment due to inadequate management of complications.
- A study involving 806 APL patients across several South American countries showed a reduction in induction mortality to 14.6% and an 81% overall survival rate over four years, demonstrating the benefits of international clinical collaboration.
Autologous stem cell transplant (ASCT) is a widely used and safe procedure to treat mostly hematologic diseases. These patients are at risk of infectious complications, which represents a major cause of morbidity and it is the second cause of mortality. This retrospective 12-year analysis of the incidence, type, and severity of infections in 266 consecutive unselected ASCT patients at our institution provides novel information addressing this issue.
View Article and Find Full Text PDFArticle Synopsis
- Myelofibrosis (MF) is a serious blood cancer that leads to low blood cell counts and various symptoms, especially in patients with low platelet levels (thrombocytopenia).
- A study examined the quality of life and symptom severity in 418 MF patients, showing that those with thrombocytopenia had significantly worse symptoms and higher total symptom scores compared to those without.
- Patients with severe thrombocytopenia faced even higher risks of anemia and other complications, highlighting the need for improved treatment options for these individuals.
Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab.
J Investig Med High Impact Case Rep
February 2017
Rituximab (R), a chimeric monoclonal antibody targeting CD20 antigen on B-cells, has become a standard of care in the treatment of B-cell malignancies, most often in conjunction with cytotoxic chemotherapy. Activity has been demonstrated in many subtypes of B-cell lymphoma, including diffuse large cell lymphoma, follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), lymphocyte-predominant Hodgkin lymphoma, and Waldenström macroglobulinemia (WM). Additionally, dose escalation of R as a single agent has demonstrated improved activity in previously treated/poor prognosis CLL.
View Article and Find Full Text PDF